A detailed history of Royal Bank Of Canada transactions in Maxcyte, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 10,862 shares of MXCT stock, worth $38,234. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,862
Previous 9,841 10.37%
Holding current value
$38,234
Previous $38,000 10.53%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.68 - $5.06 $3,757 - $5,166
1,021 Added 10.37%
10,862 $42,000
Q2 2024

Aug 14, 2024

BUY
$3.63 - $5.0 $20,175 - $27,790
5,558 Added 129.77%
9,841 $38,000
Q1 2024

Nov 05, 2024

SELL
$3.94 - $5.38 $21,898 - $29,902
-5,558 Reduced 56.48%
4,283 $17,000
Q1 2024

May 15, 2024

SELL
$3.94 - $5.38 $76,625 - $104,630
-19,448 Reduced 81.95%
4,283 $17,000
Q4 2023

Feb 14, 2024

BUY
$2.6 - $5.24 $20,701 - $41,720
7,962 Added 50.49%
23,731 $111,000
Q3 2023

Nov 14, 2023

BUY
$3.02 - $5.1 $19,953 - $33,695
6,607 Added 72.11%
15,769 $49,000
Q2 2023

Aug 14, 2023

BUY
$3.69 - $5.35 $15,095 - $21,886
4,091 Added 80.67%
9,162 $42,000
Q1 2023

May 15, 2023

SELL
$4.03 - $5.89 $27,295 - $39,892
-6,773 Reduced 57.19%
5,071 $25,000
Q4 2022

Feb 14, 2023

BUY
$4.92 - $7.4 $52,245 - $78,580
10,619 Added 866.86%
11,844 $64,000
Q3 2022

Nov 14, 2022

BUY
$4.52 - $6.51 $2,576 - $3,710
570 Added 87.02%
1,225 $8,000
Q2 2022

Aug 15, 2022

SELL
$3.59 - $6.81 $20,287 - $38,483
-5,651 Reduced 89.61%
655 $3,000
Q1 2022

May 16, 2022

SELL
$5.26 - $10.84 $74,707 - $153,960
-14,203 Reduced 69.25%
6,306 $44,000
Q4 2021

Feb 14, 2022

BUY
$8.87 - $12.94 $164,955 - $240,645
18,597 Added 972.65%
20,509 $209,000
Q3 2021

Nov 15, 2021

BUY
$12.21 - $17.2 $23,345 - $32,886
1,912 New
1,912 $23,000

Others Institutions Holding MXCT

About MAXCYTE, INC.


  • Ticker MXCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 101,724,000
  • Market Cap $358M
  • Description
  • MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...
More about MXCT
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.